NCT06511232 Intraosseous Morphine Administration During Anterior Cruciate Ligament Reconstruction
| NCT ID | NCT06511232 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | The Methodist Hospital Research Institute |
| Condition | Anterior Cruciate Ligament Tear |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2024-08-19 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 84 participants in total. It began in 2024-08-19 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine if intraosseous (IO) morphine decreases pain and post-operative opioid use in patients undergoing anterior cruciate ligament (ACL) reconstruction.
Eligibility Criteria
Inclusion Criteria: * Patients of the IRB approved surgeon(s) undergoing ACL reconstruction with bone-to-bone (BTB) autograft * Patients aged between 18-40 years old at the time of surgery Exclusion Criteria: * Patients undergoing ACL reconstruction with any other type of autograft or allograft other than BTB * Patients younger than 18 years old or older than 40 years old * Patients undergoing meniscal root repair or any other repair that changes their weight-bearing status * Patients with a history of substance abuse * Vulnerable populations * Patients on chronic pain medication within the last 6 months * BMI \>/= 35 * Allergy to morphine * Unwilling to participate * Any additional reason the PI deems reasonable
Contact & Investigator
Robert Jack, MD
PRINCIPAL INVESTIGATOR
The Methodist Hospital Research Institute
Frequently Asked Questions
Who can join the NCT06511232 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying Anterior Cruciate Ligament Tear. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06511232 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06511232 currently recruiting?
Yes, NCT06511232 is actively recruiting participants. Contact the research team at hmgoble@houstonmethodist.org for enrollment information.
Where is the NCT06511232 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT06511232 clinical trial?
NCT06511232 is sponsored by The Methodist Hospital Research Institute. The principal investigator is Robert Jack, MD at The Methodist Hospital Research Institute. The trial plans to enroll 84 participants.